{
  "biblioSummaryInfoArray": {
    "biblioSummaryInfo": {
      "applicationDate": "2015.02.23",
      "applicationFlag": "",
      "applicationNumber": "10-2015-0025384",
      "claimCount": "4",
      "examinerName": "민경난",
      "finalDisposal": "등록결정(일반)",
      "inventionTitle": "티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물",
      "inventionTitleEng": "THIENODIAZEPINE DERIVATIVES OR PHARMACEUTICALLY  ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL  COMPOSITION COMPRISING THE SAME AS AN ACTIVE  INGREDIENT",
      "openDate": "2016.08.31",
      "openNumber": "10-2016-0102821",
      "originalApplicationDate": "",
      "originalApplicationKind": "국내출원/신규",
      "originalApplicationNumber": "",
      "originalExaminationRequestDate": "2015.02.23",
      "originalExaminationRequestFlag": "Y",
      "publicationDate": "2016.11.14",
      "publicationNumber": "",
      "registerDate": "2016.11.08",
      "registerNumber": "10-1675984-0000",
      "registerStatus": "등록",
      "translationSubmitDate": ""
    }
  },
  "ipcInfoArray": {
    "ipcInfo": [
      {
        "ipcDate": "(2006.01.01)",
        "ipcNumber": "C07D 495/04"
      },
      {
        "ipcDate": "(2006.01.01)",
        "ipcNumber": "A61K 31/5517"
      },
      {
        "ipcDate": "(2006.01.01)",
        "ipcNumber": "A61K 9/16"
      },
      {
        "ipcDate": "(2006.01.01)",
        "ipcNumber": "A61K 9/20"
      },
      {
        "ipcDate": "(2006.01.01)",
        "ipcNumber": "A61K 9/48"
      }
    ]
  },
  "abstractInfoArray": {
    "abstractInfo": {
      "astrtCont": "본 발명은 신규한 티에노디아제핀 유도체, 이의 약학적으로 허용가능한 염, 및 이를 포함하는 약학적 조성물에 관한 것이다. 본 발명에 따른 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염은 c-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, RET 등과 같은 단백질 키나아제에 대해 선택적인 저해 활성을 나타내어 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물로 이용될 수 있다."
    }
  },
  "claims": {
    "application_number": "1020150025384",
    "total_amendments": 3,
    "first_version": {
      "version": 1,
      "receipt_date": "20150223",
      "document_name": "[특허출원]특허출원서",
      "claim_count": 6,
      "claims": [
        {
          "claim_number": 1,
          "claim_type": "independent",
          "change_type": "신규",
          "change_code": "I",
          "text": "하기 화학식 1로 표시되는 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:\n[화학식 1]\n[이미지]\n상기 화학식 1에서, \nAr은 치환 또는 비치환된 탄소수 6 내지 20의 아릴렌 또는 치환 또는 비치환된 탄소수 5 내지 20의 헤테로아릴렌이고;\nL은 -NR1-C(=O)-, -C(=O)-NR1-, -C(=O)-NR1-C(=O)-, -NR1-C(=O)-NR2-, 또는 -NR1-C(=O)-NR2-C(=O)-이고, 상기 R1 및 R2는 각각 독립적으로 수소, 탄소수 1 내지 5 알킬, 탄소수 2 내지 6의 불포화 알킬, 또는 탄소수 1 내지 5의 알킬아민이고;\nRa는 탄소수 6 내지 20의 아릴, 탄소수 7 내지 20의 알킬아릴, 탄소수 7 내지 20의 아릴알킬, 탄소수 5 내지 20의 헤테로아릴, 탄소수 3 내지 20의 사이클로알킬, 또는 탄소수 3 내지 20의 헤테로사이클로알킬이고; 상기 Ra에 포함된 적어도 하나의 수소는 할로겐, 할로겐화 알킬, 하이드록시기, 카보닐기, 시아노기, 알콕시기, 탄소수 3 내지 20의 헤테로사이클로알킬기, 또는 탄소수 6 내지 20의 아릴기로 치환되거나 치환되지 않는다.",
          "refers_to": []
        },
        {
          "claim_number": 2,
          "claim_type": "dependent",
          "change_type": "신규",
          "change_code": "I",
          "text": "청구항 1에 있어서, \n상기 Ra는 3-클로로-3-(트리플루오로메틸)페닐 (3-chloro-4-(trifluoromethyl)phenyl), 4-클로로-3-(트리플루오로메틸)페닐 (4-chloro-4-(trifluoromethyl)phenyl), 3-(트리플루오로메틸)페닐 (3-(trifluoromethyl)phenyl), 3-(4-메틸-1H-이미다졸-1-일)-5-(트리플루오로메틸)페닐 (3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-5-트리플루오로메틸)페닐 (3-(morpholin-4-yl)-5-(trifluoromethyl)phenyl), 4-(몰폴린-4-일)-3-(트리플루오로메틸)페닐 (4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-4-(트리플루오로메틸)페닐 (3-(morpholin-4-yl)-4-(trifluoromethyl)phenyl), 3-(몰폴린-3-일)-5-(트리플루오로메틸)페닐 (3-(morpholin-3-yl)-5-(trifluoromethyl)phenyl), 비페닐-4-일 (biphenyl-4-yl), 비페닐-2-일 (biphenyl-2-yl), 1-페닐-5-(트리플루오로메틸)-피라졸-4-일 (1-phenyl-5-(trifluoromethyl)-pyrazole-4-yl), 1-아세틸피페리딘-4-일 (1-acetylpiperidin-4-yl), 비스(4-클로로페닐)메틸 (bis(4-chlorophenyl)methyl), 2-클로로-5-(4-클로로벤질)페닐 (2-chloro-5-(4-chlorobenzyl)phenyl), 피리디닐 (pyridinyl), 피라진일 (pyrazinyl), 6-플루오로페닐-메틸 (6-fluorophenyl-methyl), 3-(4-메틸피페라진-1-일-5-(트리플루오로메틸)페닐 (3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 3-(4-히드록시피페리딘-1-일)-5-(트리플루오로메틸)페닐 (3-(4-hydroxylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 4-(4-메틸피페라진-1-일)-3-(트리플루오로메틸)페닐 (4-(4-ethylpiperazin-1-yl)-3-(trifluoromethyl)phenyl), 4-((4-에틸피페라진-1-일)메틸)-3-(트피플루오로메틸)페닐 (4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl), 4-(1-메틸피페라진-4-일옥시)-3-(트리플루오로메틸)페닐 (4-(1-methylpiperazin-4-yloxy)-3-(trifluoromethyl)phenyl), 클로로페닐 (chlorophenyl), 1H-인돌-3-일-메틸 (1H-indol-3-yl-methyl), 2-[(2-시아노페닐)설파닐]페닐 (2-[(2-cyanophenyl)sulfanyl]phenyl), 퀴놀린 (quinolinyl), 비페닐-4-일-메틸 (biphenyl-4-yl-methyl), 2,4-디메틸페닐 (dimethylphenyl), 6-하이드록시-2,5,7,8-테트라메틸-3,4-디하이드로-2H-크로멘-2-일 (6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl), 2,3-디클로로페닐 (dichlorophenyl), 4-[(4-에틸피페라진-1-일)메틸]-3-(트리플루오로메틸)페닐 (4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl), 플루오로페닐 (fluorophenyl), 1H-벤조트리아졸-5-일 (1H-benzotriazol-5-yl), 5-(4-메톡시페닐)퓨란-2-일 (5-(4-methoxyphenyl)furan-2-yl), 디하이드로-1H-인돌-2-일 (dihydro-1H-indol-2-yl), (3,4-디-메톡시페닐)메틸 (3,4-di-methoxyphenyl)methyl), 나프틸 (naphthyl), 벤조티오핀일 (benzothienyl), 퓨란일 (pyranyl), 아이소옥사졸일 (isoxazolyl), 피라졸일 (pyrazolyl), 피리다진일 (pyridazinyl), 티아졸일 (thiazolyl), 티엔일 (thienyl), 피리미딘일 (pyrimidinyl), 이미다졸일 (imidazolyl), 피롤일 (pyrolyl), 디하이드로피롤일 (dihydropyrolyl), 옥사졸일 (oxazolyl), 트리아졸일 (triazolyl), 티아디아졸일 (thidiazolyl), 벤즈이미다졸일 (benzimidazolyl), 퀴놀린일 (quinolyl), 테트라하이드로퀴놀린일 (tetrahydroquinolyl), 벤조티아졸일 (benzothiazolyl), 벤조티아조페닐 (benzothiazophenyl), 벤조디옥솔일 (benzodioxolyl), 인돌일 (indolyl), 또는 디하이드로벤조퓨란일 (dihydrobenzofuranyl)인, 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염.",
          "refers_to": [
            1
          ]
        },
        {
          "claim_number": 3,
          "claim_type": "dependent",
          "change_type": "신규",
          "change_code": "I",
          "text": "청구항 1에 있어서, \n상기 화학식 1로 표시되는 화합물은 하기 화합물들로 이루어진 군에서 선택된 1종 이상의 화합물인, 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:\n4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)-3-(trifluoromethyl)benzamide;\n3-(4-methyl-1H-imidazol-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n3-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-4-carboxamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-2-carboxamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl) -1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;\n1-acetyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)piperidine-4-carboxamide;\n2,2-bis(4-chlorophenyl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)pyrazine-2-carboxamide;\n3-(4-methylpiperazin-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)benzamide;\n2-(1H-indol-3-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\n2-(2-cyanophenylthio)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)benzamide;\n2-(biphenyl-4-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\n3,5-dimethyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide;\n4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin- 4-yl)phenyl)-3-(trifluoromethyl)benzamide;\n3-(4-methyl-1H-imidazol-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n3-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4b][1,4] diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-4-carboxamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-2-carboxamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;\n1-acetyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)piperidine-4-carboxamide;\n2,2-bis(4-chlorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)pyrazine-2-carboxamide;\n3-(4-methylpiperazin-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin- 4-yl)phenyl)benzamide;\n2-(1H-indol-3-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\n2-(2-cyanophenylthio)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)benzamide;\n2-(biphenyl-4-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide;\n3,5-dimethyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide;\n2-(2-fluorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)quinoline-2-carboxamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)quinoline-3-carboxamide;\n (R)-6-hydroxy-2,5,7,8-tetramethyl-N-(3-(2-oxo-2,3-dihydro-1H- thieno[3,4-b][1,4]diazepin-4-yl)phenyl)chroman-2-carboxamide;\n1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro -1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(4-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(3-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(3,4-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea;\n1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) -3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(3,5-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(2-fluorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea;\n1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro -1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(4-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(3-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) -3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(3,4-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea;\n1-(3,5-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4] diazepin-4-yl)phenyl)urea; 및\n1-(2-fluorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea.",
          "refers_to": [
            1
          ]
        },
        {
          "claim_number": 4,
          "claim_type": "dependent",
          "change_type": "신규",
          "change_code": "I",
          "text": "청구항 1의 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물.",
          "refers_to": [
            1
          ]
        },
        {
          "claim_number": 5,
          "claim_type": "dependent",
          "change_type": "신규",
          "change_code": "I",
          "text": "청구항 4에 있어서, \nc-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, 및 RET로 이루어진 군에서 선택된 1종 이상의 단백질 키나아제에 대한 저해 활성을 갖는, 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물.",
          "refers_to": [
            4
          ]
        },
        {
          "claim_number": 6,
          "claim_type": "dependent",
          "change_type": "신규",
          "change_code": "I",
          "text": "청구항 4에 있어서, \n상기 비정상 세포 성장 질환은 위암, 폐암, 간암, 대장암, 소장암, 췌장암, 뇌암, 뼈암, 흑색종, 유방암, 경화성선증, 자궁암, 자궁경부암, 두경부암, 식도암, 갑상선암, 부갑상선암, 신장암, 육종, 전립선암, 요도암, 방광암, 혈액암, 림프종, 건선, 및 섬유선종으로 이루어진 군에서 선택된 1종 이상인, 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물.",
          "refers_to": [
            4
          ]
        }
      ]
    },
    "last_version": {
      "version": 3,
      "receipt_date": "20160803",
      "document_name": "[명세서등 보정]보정서",
      "claim_count": 6,
      "claims": [
        {
          "claim_number": 1,
          "claim_type": "independent",
          "change_type": "수정",
          "change_code": "A",
          "text": "하기 화학식 1로 표시되는 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:[화학식 1]상기 화학식 1에서, Ar은 1,4-페닐렌, 1,3-페닐렌, 1,5-나프탈렌, 또는 2,6-나프탈렌이고;L은 -NH-C(=O)-, -C(=O)-NH-, -C(=O)-NH-C(=O)-, -NH-C(=O)-NH-, 또는 -NH-C(=O)-NH-C(=O)- 이고;Ra는 3-클로로-3-(트리플루오로메틸)페닐 (3-chloro-4-(trifluoromethyl)phenyl), 4-클로로-3-(트리플루오로메틸)페닐 (4-chloro-4-(trifluoromethyl)phenyl), 3-(트리플루오로메틸)페닐 (3-(trifluoromethyl)phenyl), 3-(4-메틸-1H-이미다졸-1-일)-5-(트리플루오로메틸)페닐 (3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-5-트리플루오로메틸)페닐 (3-(morpholin-4-yl)-5-(trifluoromethyl)phenyl), 4-(몰폴린-4-일)-3-(트리플루오로메틸)페닐 (4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-4-(트리플루오로메틸)페닐 (3-(morpholin-4-yl)-4-(trifluoromethyl)phenyl), 3-(몰폴린-3-일)-5-(트리플루오로메틸)페닐 (3-(morpholin-3-yl)-5-(trifluoromethyl)phenyl), 비페닐-4-일 (biphenyl-4-yl), 비페닐-2-일 (biphenyl-2-yl), 1-페닐-5-(트리플루오로메틸)-피라졸-4-일 (1-phenyl-5-(trifluoromethyl)-pyrazole-4-yl), 1-아세틸피페리딘-4-일 (1-acetylpiperidin-4-yl), 비스(4-클로로페닐)메틸 (bis(4-chlorophenyl)methyl), 2-클로로-5-(4-클로로벤질)페닐 (2-chloro-5-(4-chlorobenzyl)phenyl), 피리디닐 (pyridinyl), 피라진일 (pyrazinyl), 6-플루오로페닐-메틸 (6-fluorophenyl-methyl), 3-(4-메틸피페라진-1-일-5-(트리플루오로메틸)페닐 (3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 3-(4-히드록시피페리딘-1-일)-5-(트리플루오로메틸)페닐 (3-(4-hydroxylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 4-(4-메틸피페라진-1-일)-3-(트리플루오로메틸)페닐 (4-(4-ethylpiperazin-1-yl)-3-(trifluoromethyl)phenyl), 4-((4-에틸피페라진-1-일)메틸)-3-(트피플루오로메틸)페닐 (4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl), 4-(1-메틸피페라진-4-일옥시)-3-(트리플루오로메틸)페닐 (4-(1-methylpiperazin-4-yloxy)-3-(trifluoromethyl)phenyl), 클로로페닐 (chlorophenyl), 1H-인돌-3-일-메틸 (1H-indol-3-yl-methyl), 2-[(2-시아노페닐)설파닐]페닐 (2-[(2-cyanophenyl)sulfanyl]phenyl), 퀴놀린 (quinolinyl), 비페닐-4-일-메틸 (biphenyl-4-yl-methyl), 디메틸페닐 (dimethylphenyl), 6-하이드록시-2,5,7,8-테트라메틸-3,4-디하이드로-2H-크로멘-2-일 (6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl), 디클로로페닐 (dichlorophenyl), 또는 플루오로페닐 (fluorophenyl)이다.",
          "refers_to": []
        },
        {
          "claim_number": 2,
          "claim_type": "independent",
          "change_type": "삭제",
          "change_code": "D",
          "text": "",
          "refers_to": []
        },
        {
          "claim_number": 3,
          "claim_type": "dependent",
          "change_type": "수정",
          "change_code": "A",
          "text": "청구항 1에 있어서, 상기 화학식 1로 표시되는 화합물은 하기 화합물들로 이루어진 군에서 선택된 1종 이상의 화합물인, 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:4-클로로-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)-3-(trifluoromethyl)benzamide);3-(4-메틸-1H-이미다졸-1-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methyl-1H-imidazol-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);3-모르폴리노-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);4-모르폴리노-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide);N-(4-(2-옥소-2,3-디히드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-4-카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)biphenyl-4-carboxamide);N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-2-카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)biphenyl-2-carboxamide);N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-1-페닐-5-(트리플루오로메틸)-1H-피라졸-4-카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide);1-아세틸-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)피페리딘-4-카르복스아미드(1-acetyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)piperidine-4-carboxamide);2,2-비스(4-클로로페닐)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2,2-bis(4-chlorophenyl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);N-(4-(2-옥소-2,3-디하이드-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아이소니코틴아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide);N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-피라진-2- 카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)pyrazine-2-carboxamide);3-(4-메틸피페라진-1-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methylpiperazin-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);4-클로로-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)benzamide);2-(1H-인돌-3-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(1H-indol-3-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);2-(2-시아노페닐티오)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(2-(2-cyanophenylthio)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)benzamide);2-(비페닐-4-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(biphenyl-4-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide);3,5-디메틸-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(3,5-dimethyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide);4-클로로-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide);3-(4-메틸-1H-이미다졸-1-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methyl-1H-imidazol-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);3-모르폴리노-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);4-모르폴리노-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-4-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-4-carboxamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-2-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)biphenyl-2-carboxamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-1-페닐-5-(트리플루오로메틸)-1H-피라졸-4-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide);1-아세틸-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)피페리딘-4-카르복스아미드(1-acetyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)piperidine-4-carboxamide);2,2-비스(4-클로로페닐)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2,2-bis(4-chlorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아이소니코틴아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)피라진-2-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)pyrazine-2-carboxamide);3-(4-메틸피페라진-1-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methylpiperazin-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);4-클로로-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)benzamide);2-(1H-인돌-3-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(1H-indol-3-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);2-(2-시아노페닐티오)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(2-(2-cyanophenylthio)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)benzamide);2-(비페닐-4-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(biphenyl-4-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide);3,5-디메틸-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(3,5-dimethyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide);2-(2-플루오로페닐)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(2-fluorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)퀴놀린-2-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)quinoline-2-carboxamide);N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)퀴놀린-3-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)quinoline-3-carboxamide);(R)-6-하이드록시-2,5,7,8-테트라메틸-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)크로만-2-카르복스아미드((R)-6-hydroxy-2,5,7,8-tetramethyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)chroman-2-carboxamide);1-(4-클로로-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(4-클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(3-클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(3,4-디클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,4-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea);1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(3,5-디클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,5-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(2-플루오로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(2-fluorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(4-클로로-3-(트리플루오로메틸)페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro -1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(4-클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(3-클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(3,4-디클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,4-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);1-(3,5-디클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,5-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea); 및1-(2-플루오로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4- 일)페닐)우레아(1-(2-fluorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea).",
          "refers_to": [
            1
          ]
        },
        {
          "claim_number": 4,
          "claim_type": "dependent",
          "change_type": "수정",
          "change_code": "A",
          "text": "청구항 1의 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 흑색종의 예방 또는 치료용 약학적 조성물.",
          "refers_to": [
            1
          ]
        },
        {
          "claim_number": 5,
          "claim_type": "independent",
          "change_type": "수정",
          "change_code": "A",
          "text": "1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하고, c-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, 및 RET로 이루어진 군에서 선택된 1종 이상의 단백질 키나아제에 대한 저해 활성을 갖는,위암, 폐암, 간암, 대장암, 소장암, 췌장암, 뇌암, 뼈암, 흑색종, 유방암, 경화성선증, 자궁암, 자궁경부암, 두경부암, 식도암, 갑상선암, 부갑상선암, 신장암, 육종, 전립선암, 요도암, 방광암, 혈액암, 림프종, 건선, 또는 섬유선종의 예방 또는 치료용 약학적 조성물.",
          "refers_to": []
        },
        {
          "claim_number": 6,
          "claim_type": "independent",
          "change_type": "삭제",
          "change_code": "D",
          "text": "",
          "refers_to": []
        }
      ]
    },
    "all_versions": [
      {
        "version": 1,
        "receipt_date": "20150223",
        "document_name": "[특허출원]특허출원서",
        "claim_count": 6,
        "claims": [
          {
            "claim_number": 1,
            "claim_type": "independent",
            "change_type": "신규",
            "change_code": "I",
            "text": "하기 화학식 1로 표시되는 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:\n[화학식 1]\n[이미지]\n상기 화학식 1에서, \nAr은 치환 또는 비치환된 탄소수 6 내지 20의 아릴렌 또는 치환 또는 비치환된 탄소수 5 내지 20의 헤테로아릴렌이고;\nL은 -NR1-C(=O)-, -C(=O)-NR1-, -C(=O)-NR1-C(=O)-, -NR1-C(=O)-NR2-, 또는 -NR1-C(=O)-NR2-C(=O)-이고, 상기 R1 및 R2는 각각 독립적으로 수소, 탄소수 1 내지 5 알킬, 탄소수 2 내지 6의 불포화 알킬, 또는 탄소수 1 내지 5의 알킬아민이고;\nRa는 탄소수 6 내지 20의 아릴, 탄소수 7 내지 20의 알킬아릴, 탄소수 7 내지 20의 아릴알킬, 탄소수 5 내지 20의 헤테로아릴, 탄소수 3 내지 20의 사이클로알킬, 또는 탄소수 3 내지 20의 헤테로사이클로알킬이고; 상기 Ra에 포함된 적어도 하나의 수소는 할로겐, 할로겐화 알킬, 하이드록시기, 카보닐기, 시아노기, 알콕시기, 탄소수 3 내지 20의 헤테로사이클로알킬기, 또는 탄소수 6 내지 20의 아릴기로 치환되거나 치환되지 않는다.",
            "refers_to": []
          },
          {
            "claim_number": 2,
            "claim_type": "dependent",
            "change_type": "신규",
            "change_code": "I",
            "text": "청구항 1에 있어서, \n상기 Ra는 3-클로로-3-(트리플루오로메틸)페닐 (3-chloro-4-(trifluoromethyl)phenyl), 4-클로로-3-(트리플루오로메틸)페닐 (4-chloro-4-(trifluoromethyl)phenyl), 3-(트리플루오로메틸)페닐 (3-(trifluoromethyl)phenyl), 3-(4-메틸-1H-이미다졸-1-일)-5-(트리플루오로메틸)페닐 (3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-5-트리플루오로메틸)페닐 (3-(morpholin-4-yl)-5-(trifluoromethyl)phenyl), 4-(몰폴린-4-일)-3-(트리플루오로메틸)페닐 (4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-4-(트리플루오로메틸)페닐 (3-(morpholin-4-yl)-4-(trifluoromethyl)phenyl), 3-(몰폴린-3-일)-5-(트리플루오로메틸)페닐 (3-(morpholin-3-yl)-5-(trifluoromethyl)phenyl), 비페닐-4-일 (biphenyl-4-yl), 비페닐-2-일 (biphenyl-2-yl), 1-페닐-5-(트리플루오로메틸)-피라졸-4-일 (1-phenyl-5-(trifluoromethyl)-pyrazole-4-yl), 1-아세틸피페리딘-4-일 (1-acetylpiperidin-4-yl), 비스(4-클로로페닐)메틸 (bis(4-chlorophenyl)methyl), 2-클로로-5-(4-클로로벤질)페닐 (2-chloro-5-(4-chlorobenzyl)phenyl), 피리디닐 (pyridinyl), 피라진일 (pyrazinyl), 6-플루오로페닐-메틸 (6-fluorophenyl-methyl), 3-(4-메틸피페라진-1-일-5-(트리플루오로메틸)페닐 (3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 3-(4-히드록시피페리딘-1-일)-5-(트리플루오로메틸)페닐 (3-(4-hydroxylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 4-(4-메틸피페라진-1-일)-3-(트리플루오로메틸)페닐 (4-(4-ethylpiperazin-1-yl)-3-(trifluoromethyl)phenyl), 4-((4-에틸피페라진-1-일)메틸)-3-(트피플루오로메틸)페닐 (4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl), 4-(1-메틸피페라진-4-일옥시)-3-(트리플루오로메틸)페닐 (4-(1-methylpiperazin-4-yloxy)-3-(trifluoromethyl)phenyl), 클로로페닐 (chlorophenyl), 1H-인돌-3-일-메틸 (1H-indol-3-yl-methyl), 2-[(2-시아노페닐)설파닐]페닐 (2-[(2-cyanophenyl)sulfanyl]phenyl), 퀴놀린 (quinolinyl), 비페닐-4-일-메틸 (biphenyl-4-yl-methyl), 2,4-디메틸페닐 (dimethylphenyl), 6-하이드록시-2,5,7,8-테트라메틸-3,4-디하이드로-2H-크로멘-2-일 (6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl), 2,3-디클로로페닐 (dichlorophenyl), 4-[(4-에틸피페라진-1-일)메틸]-3-(트리플루오로메틸)페닐 (4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl), 플루오로페닐 (fluorophenyl), 1H-벤조트리아졸-5-일 (1H-benzotriazol-5-yl), 5-(4-메톡시페닐)퓨란-2-일 (5-(4-methoxyphenyl)furan-2-yl), 디하이드로-1H-인돌-2-일 (dihydro-1H-indol-2-yl), (3,4-디-메톡시페닐)메틸 (3,4-di-methoxyphenyl)methyl), 나프틸 (naphthyl), 벤조티오핀일 (benzothienyl), 퓨란일 (pyranyl), 아이소옥사졸일 (isoxazolyl), 피라졸일 (pyrazolyl), 피리다진일 (pyridazinyl), 티아졸일 (thiazolyl), 티엔일 (thienyl), 피리미딘일 (pyrimidinyl), 이미다졸일 (imidazolyl), 피롤일 (pyrolyl), 디하이드로피롤일 (dihydropyrolyl), 옥사졸일 (oxazolyl), 트리아졸일 (triazolyl), 티아디아졸일 (thidiazolyl), 벤즈이미다졸일 (benzimidazolyl), 퀴놀린일 (quinolyl), 테트라하이드로퀴놀린일 (tetrahydroquinolyl), 벤조티아졸일 (benzothiazolyl), 벤조티아조페닐 (benzothiazophenyl), 벤조디옥솔일 (benzodioxolyl), 인돌일 (indolyl), 또는 디하이드로벤조퓨란일 (dihydrobenzofuranyl)인, 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염.",
            "refers_to": [
              1
            ]
          },
          {
            "claim_number": 3,
            "claim_type": "dependent",
            "change_type": "신규",
            "change_code": "I",
            "text": "청구항 1에 있어서, \n상기 화학식 1로 표시되는 화합물은 하기 화합물들로 이루어진 군에서 선택된 1종 이상의 화합물인, 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:\n4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)-3-(trifluoromethyl)benzamide;\n3-(4-methyl-1H-imidazol-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n3-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-4-carboxamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-2-carboxamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl) -1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;\n1-acetyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)piperidine-4-carboxamide;\n2,2-bis(4-chlorophenyl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide;\nN-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)pyrazine-2-carboxamide;\n3-(4-methylpiperazin-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)benzamide;\n2-(1H-indol-3-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\n2-(2-cyanophenylthio)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)benzamide;\n2-(biphenyl-4-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\n3,5-dimethyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide;\n4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin- 4-yl)phenyl)-3-(trifluoromethyl)benzamide;\n3-(4-methyl-1H-imidazol-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n3-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4b][1,4] diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-4-carboxamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-2-carboxamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;\n1-acetyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)piperidine-4-carboxamide;\n2,2-bis(4-chlorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)pyrazine-2-carboxamide;\n3-(4-methylpiperazin-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide;\n4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin- 4-yl)phenyl)benzamide;\n2-(1H-indol-3-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide;\n2-(2-cyanophenylthio)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)benzamide;\n2-(biphenyl-4-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide;\n3,5-dimethyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide;\n2-(2-fluorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)quinoline-2-carboxamide;\nN-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)quinoline-3-carboxamide;\n (R)-6-hydroxy-2,5,7,8-tetramethyl-N-(3-(2-oxo-2,3-dihydro-1H- thieno[3,4-b][1,4]diazepin-4-yl)phenyl)chroman-2-carboxamide;\n1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro -1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(4-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(3-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(3,4-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea;\n1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) -3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(3,5-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(2-fluorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea;\n1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro -1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(4-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(3-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)urea;\n1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl) -3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea;\n1-(3,4-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea;\n1-(3,5-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4] diazepin-4-yl)phenyl)urea; 및\n1-(2-fluorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea.",
            "refers_to": [
              1
            ]
          },
          {
            "claim_number": 4,
            "claim_type": "dependent",
            "change_type": "신규",
            "change_code": "I",
            "text": "청구항 1의 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물.",
            "refers_to": [
              1
            ]
          },
          {
            "claim_number": 5,
            "claim_type": "dependent",
            "change_type": "신규",
            "change_code": "I",
            "text": "청구항 4에 있어서, \nc-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, 및 RET로 이루어진 군에서 선택된 1종 이상의 단백질 키나아제에 대한 저해 활성을 갖는, 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물.",
            "refers_to": [
              4
            ]
          },
          {
            "claim_number": 6,
            "claim_type": "dependent",
            "change_type": "신규",
            "change_code": "I",
            "text": "청구항 4에 있어서, \n상기 비정상 세포 성장 질환은 위암, 폐암, 간암, 대장암, 소장암, 췌장암, 뇌암, 뼈암, 흑색종, 유방암, 경화성선증, 자궁암, 자궁경부암, 두경부암, 식도암, 갑상선암, 부갑상선암, 신장암, 육종, 전립선암, 요도암, 방광암, 혈액암, 림프종, 건선, 및 섬유선종으로 이루어진 군에서 선택된 1종 이상인, 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물.",
            "refers_to": [
              4
            ]
          }
        ]
      },
      {
        "version": 2,
        "receipt_date": "20160519",
        "document_name": "[명세서등 보정]보정서",
        "claim_count": 6,
        "claims": [
          {
            "claim_number": 1,
            "claim_type": "independent",
            "change_type": "수정",
            "change_code": "A",
            "text": "하기 화학식 1로 표시되는 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:\n[화학식 1]\n[이미지]\n상기 화학식 1에서, \nAr은 1,4-페닐렌, 1,3-페닐렌, 1,5-나프탈렌, 또는 2,6-나프탈렌이고;\nL은 -NH-C(=O)-, -C(=O)-NH-, -C(=O)-NH-C(=O)-, -NH-C(=O)-NH-, 또는 -NH-C(=O)-NH-C(=O)- 이고;\nRa는 3-클로로-3-(트리플루오로메틸)페닐 (3-chloro-4-(trifluoromethyl)phenyl), 4-클로로-3-(트리플루오로메틸)페닐 (4-chloro-4-(trifluoromethyl)phenyl), 3-(트리플루오로메틸)페닐 (3-(trifluoromethyl)phenyl), 3-(4-메틸-1H-이미다졸-1-일)-5-(트리플루오로메틸)페닐 (3-(4-methyl-1H-imidazole-1-yl)-5-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-5-트리플루오로메틸)페닐 (3-(morpholin-4-yl)-5-(trifluoromethyl)phenyl), 4-(몰폴린-4-일)-3-(트리플루오로메틸)페닐 (4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl), 3-(몰폴린-4-일)-4-(트리플루오로메틸)페닐 (3-(morpholin-4-yl)-4-(trifluoromethyl)phenyl), 3-(몰폴린-3-일)-5-(트리플루오로메틸)페닐 (3-(morpholin-3-yl)-5-(trifluoromethyl)phenyl), 비페닐-4-일 (biphenyl-4-yl), 비페닐-2-일 (biphenyl-2-yl), 1-페닐-5-(트리플루오로메틸)-피라졸-4-일 (1-phenyl-5-(trifluoromethyl)-pyrazole-4-yl), 1-아세틸피페리딘-4-일 (1-acetylpiperidin-4-yl), 비스(4-클로로페닐)메틸 (bis(4-chlorophenyl)methyl), 2-클로로-5-(4-클로로벤질)페닐 (2-chloro-5-(4-chlorobenzyl)phenyl), 피리디닐 (pyridinyl), 피라진일 (pyrazinyl), 6-플루오로페닐-메틸 (6-fluorophenyl-methyl), 3-(4-메틸피페라진-1-일-5-(트리플루오로메틸)페닐 (3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 3-(4-히드록시피페리딘-1-일)-5-(트리플루오로메틸)페닐 (3-(4-hydroxylpiperazin-1-yl)-5-(trifluoromethyl)phenyl), 4-(4-메틸피페라진-1-일)-3-(트리플루오로메틸)페닐 (4-(4-ethylpiperazin-1-yl)-3-(trifluoromethyl)phenyl), 4-((4-에틸피페라진-1-일)메틸)-3-(트피플루오로메틸)페닐 (4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl), 4-(1-메틸피페라진-4-일옥시)-3-(트리플루오로메틸)페닐 (4-(1-methylpiperazin-4-yloxy)-3-(trifluoromethyl)phenyl), 클로로페닐 (chlorophenyl), 1H-인돌-3-일-메틸 (1H-indol-3-yl-methyl), 2-[(2-시아노페닐)설파닐]페닐 (2-[(2-cyanophenyl)sulfanyl]phenyl), 퀴놀린 (quinolinyl), 비페닐-4-일-메틸 (biphenyl-4-yl-methyl), 디메틸페닐 (dimethylphenyl), 6-하이드록시-2,5,7,8-테트라메틸-3,4-디하이드로-2H-크로멘-2-일 (6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl), 디클로로페닐 (dichlorophenyl), 또는 플루오로페닐 (fluorophenyl)이다.",
            "refers_to": []
          },
          {
            "claim_number": 2,
            "claim_type": "independent",
            "change_type": "삭제",
            "change_code": "D",
            "text": "",
            "refers_to": []
          },
          {
            "claim_number": 3,
            "claim_type": "dependent",
            "change_type": "수정",
            "change_code": "A",
            "text": "청구항 1에 있어서, \n상기 화학식 1로 표시되는 화합물은 하기 화합물들로 이루어진 군에서 선택된 1종 이상의 화합물인, 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염:\n4-클로로-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin -4-yl)phenyl)-3-(trifluoromethyl)benzamide);\n3-(4-메틸-1H-이미다졸-1-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methyl-1H-imidazol-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);\n3-모르폴리노-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);\n4-모르폴리노-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-morpholino-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide);\nN-(4-(2-옥소-2,3-디히드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-4-카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)biphenyl-4-carboxamide);\nN-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-2-카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)biphenyl-2-carboxamide);\nN-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-1-페닐-5-(트리플루오로메틸)-1H-피라졸-4-카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide);\n1-아세틸-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)피페리딘-4-카르복스아미드(1-acetyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)piperidine-4-carboxamide);\n2,2-비스(4-클로로페닐)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2,2-bis(4-chlorophenyl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);\nN-(4-(2-옥소-2,3-디하이드-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아이소니코틴아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide);\nN-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-피라진-2- 카르복스아미드(N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)pyrazine-2-carboxamide);\n3-(4-메틸피페라진-1-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methylpiperazin-1-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);\n4-클로로-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(4-chloro-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)benzamide);\n2-(1H-인돌-3-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(1H-indol-3-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);\n2-(2-시아노페닐티오)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(2-(2-cyanophenylthio)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)benzamide);\n2-(비페닐-4-일)-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(biphenyl-4-yl)-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)acetamide);\n3,5-디메틸-N-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(3,5-dimethyl-N-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide);\n4-클로로-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide);\n3-(4-메틸-1H-이미다졸-1-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methyl-1H-imidazol-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);\n3-모르폴리노-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);\n4-모르폴리노-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-3-(트리플루오로메틸)벤즈아미드(4-morpholino-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)-3-(trifluoromethyl)benzamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-4-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)biphenyl-4-carboxamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)비페닐-2-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)biphenyl-2-carboxamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-1-페닐-5-(트리플루오로메틸)-1H-피라졸-4-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide);\n1-아세틸-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)피페리딘-4-카르복스아미드(1-acetyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)piperidine-4-carboxamide);\n2,2-비스(4-클로로페닐)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2,2-bis(4-chlorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아이소니코틴아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl) phenyl)isonicotinamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)피라진-2-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)pyrazine-2-carboxamide);\n3-(4-메틸피페라진-1-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)-5-(트리플루오로메틸)벤즈아미드(3-(4-methylpiperazin-1-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)-5-(trifluoromethyl)benzamide);\n4-클로로-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(4-chloro-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)benzamide);\n2-(1H-인돌-3-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(1H-indol-3-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)acetamide);\n2-(2-시아노페닐티오)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(2-(2-cyanophenylthio)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)benzamide);\n2-(비페닐-4-일)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(biphenyl-4-yl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide);\n3,5-디메틸-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)벤즈아미드(3,5-dimethyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)benzamide);\n2-(2-플루오로페닐)-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)아세트아미드(2-(2-fluorophenyl)-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4] diazepin-4-yl)phenyl)acetamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)퀴놀린-2-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)quinoline-2-carboxamide);\nN-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)퀴놀린-3-카르복스아미드(N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)quinoline-3-carboxamide);\n(R)-6-하이드록시-2,5,7,8-테트라메틸-N-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)크로만-2-카르복스아미드((R)-6-hydroxy-2,5,7,8-tetramethyl-N-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)chroman-2-carboxamide);\n1-(4-클로로-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(4-클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(3-클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3-chlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(3,4-디클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,4-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea);\n1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(3,5-디클로로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,5-dichlorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(2-플루오로페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(2-fluorophenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(4-클로로-3-(트리플루오로메틸)페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro -1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(4-클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(3-클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3-chlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(3,4-디클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,4-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea);\n1-(3,5-디클로로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(3,5-dichlorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea); 및\n1-(2-플루오로페닐)-3-(3-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4- 일)페닐)우레아(1-(2-fluorophenyl)-3-(3-(2-oxo-2,3-dihydro-1H-thieno[3,4-b] [1,4]diazepin-4-yl)phenyl)urea).",
            "refers_to": [
              1
            ]
          },
          {
            "claim_number": 4,
            "claim_type": "dependent",
            "change_type": "수정",
            "change_code": "A",
            "text": "청구항 1의 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 흑색종의 예방 또는 치료용 약학적 조성물.",
            "refers_to": [
              1
            ]
          },
          {
            "claim_number": 5,
            "claim_type": "independent",
            "change_type": "수정",
            "change_code": "A",
            "text": "1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하고, \nc-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, 및 RET로 이루어진 군에서 선택된 1종 이상의 단백질 키나아제에 대한 저해 활성을 갖는 약학적 조성물.",
            "refers_to": []
          },
          {
            "claim_number": 6,
            "claim_type": "independent",
            "change_type": "삭제",
            "change_code": "D",
            "text": "",
            "refers_to": []
          }
        ]
      },
      {
        "version": 3,
        "receipt_date": "20160803",
        "document_name": "[명세서등 보정]보정서",
        "claim_count": 1,
        "claims": [
          {
            "claim_number": 5,
            "claim_type": "independent",
            "change_type": "수정",
            "change_code": "A",
            "text": "1-(4-((4-에틸피페라진-1-일)메틸)-3-(트리플루오로메틸)페닐)-3-(4-(2-옥소-2,3-디하이드로-1H-티에노[3,4-b][1,4]디아제핀-4-일)페닐)우레아(1-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno[3,4-b][1,4]diazepin-4-yl)phenyl)urea) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하고, \nc-Kit, FLT3, FMS, LYN, RAF1, VEGFR3, PDGFRa, PDGFRb, 및 RET로 이루어진 군에서 선택된 1종 이상의 단백질 키나아제에 대한 저해 활성을 갖는,\n위암, 폐암, 간암, 대장암, 소장암, 췌장암, 뇌암, 뼈암, 흑색종, 유방암, 경화성선증, 자궁암, 자궁경부암, 두경부암, 식도암, 갑상선암, 부갑상선암, 신장암, 육종, 전립선암, 요도암, 방광암, 혈액암, 림프종, 건선, 또는 섬유선종의 예방 또는 치료용 약학적 조성물.",
            "refers_to": []
          }
        ]
      }
    ],
    "summary": {
      "before_claim_count": 6,
      "after_claim_count": 1,
      "total_versions": 3
    }
  },
  "familyInfoArray": {
    "familyInfo": ""
  },
  "internationalInfoArray": {
    "internationalInfo": {
      "internationOpenDate": "",
      "internationOpenNumber": "",
      "internationalApplicationDate": "",
      "internationalApplicationNumber": ""
    }
  },
  "applicantInfoArray": {
    "applicantInfo": {
      "address": "경기도 안산시 상록구...",
      "code": "120120008551",
      "country": "대한민국",
      "engName": "Industry-University Cooperation Foundation Hanyang University ERICA Campus",
      "name": "한양대학교 에리카산학협력단"
    }
  },
  "inventorInfoArray": {
    "inventorInfo": [
      {
        "address": "서울특별시 강남구...",
        "code": "",
        "country": "대한민국",
        "engName": "HAH, JUNG-MI",
        "name": "하정미"
      },
      {
        "address": "경기도 수원시 영통구...",
        "code": "",
        "country": "대한민국",
        "engName": "LEE, JUNG HUN",
        "name": "이정헌"
      },
      {
        "address": "서울특별시 도봉구...",
        "code": "",
        "country": "대한민국",
        "engName": "KIM, MINJUNG",
        "name": "김민정"
      }
    ]
  },
  "agentInfoArray": {
    "agentInfo": {
      "address": "서울특별시 강남구 테헤란로 ***, 서림빌딩 **층 (역삼동)",
      "code": "920011000036",
      "country": "대한민국",
      "engName": "YOU ME PATENT & LAW FIRM",
      "name": "유미특허법인"
    }
  },
  "priorityInfoArray": "",
  "designatedStateInfoArray": "",
  "priorArtDocumentsInfoArray": {
    "priorArtDocumentsInfo": [
      {
        "documentsNumber": "KR1019920003981 B1",
        "examinerQuotationFlag": ""
      },
      {
        "documentsNumber": "US4900729",
        "examinerQuotationFlag": ""
      },
      {
        "documentsNumber": "Chimirri, A., et al. Farmaco. 1994, 49(3), 193-196",
        "examinerQuotationFlag": ""
      },
      {
        "documentsNumber": "Chimirri, A., et al. Heterocycles. 1992, 34(6), 1191-1200",
        "examinerQuotationFlag": ""
      }
    ]
  },
  "legalStatusInfoArray": {
    "legalStatusInfo": [
      {
        "commonCodeName": "수리 (Accepted)",
        "documentEngName": "[Patent Application] Patent Application",
        "documentName": "[특허출원]특허출원서",
        "receiptDate": "2015.02.23",
        "receiptNumber": "1-1-2015-0177811-27"
      },
      {
        "commonCodeName": "수리 (Accepted)",
        "documentEngName": "[Amendment to Patent Application, etc.] Amendment",
        "documentName": "[출원서등 보정]보정서",
        "receiptDate": "2015.06.10",
        "receiptNumber": "1-1-2015-0559246-90"
      },
      {
        "commonCodeName": "수리 (Accepted)",
        "documentEngName": "Request for Prior Art Search",
        "documentName": "선행기술조사의뢰서",
        "receiptDate": "2016.01.12",
        "receiptNumber": "9-1-9999-9999999-89"
      },
      {
        "commonCodeName": "발송처리완료 (Completion of Transmission)",
        "documentEngName": "Report of Prior Art Search",
        "documentName": "선행기술조사보고서",
        "receiptDate": "2016.03.18",
        "receiptNumber": "9-6-2016-0030646-92"
      },
      {
        "commonCodeName": "발송처리완료 (Completion of Transmission)",
        "documentEngName": "Notification of reason for refusal",
        "documentName": "의견제출통지서",
        "receiptDate": "2016.03.21",
        "receiptNumber": "9-5-2016-0209254-72"
      },
      {
        "commonCodeName": "보정승인간주 (Regarded as an acceptance of amendment)",
        "documentEngName": "[Amendment to Description, etc.] Amendment",
        "documentName": "[명세서등 보정]보정서",
        "receiptDate": "2016.05.19",
        "receiptNumber": "1-1-2016-0481471-39"
      },
      {
        "commonCodeName": "수리 (Accepted)",
        "documentEngName": "[Opinion according to the Notification of Reasons for Refusal] Written Opinion(Written Reply, Written Substantiation)",
        "documentName": "[거절이유 등 통지에 따른 의견]의견(답변, 소명)서",
        "receiptDate": "2016.05.19",
        "receiptNumber": "1-1-2016-0481477-13"
      },
      {
        "commonCodeName": "발송처리완료 (Completion of Transmission)",
        "documentEngName": "Notification of reason for final refusal",
        "documentName": "최후의견제출통지서",
        "receiptDate": "2016.06.03",
        "receiptNumber": "9-5-2016-0410879-57"
      },
      {
        "commonCodeName": "수리 (Accepted)",
        "documentEngName": "[Opinion according to the Notification of Reasons for Refusal] Written Opinion(Written Reply, Written Substantiation)",
        "documentName": "[거절이유 등 통지에 따른 의견]의견(답변, 소명)서",
        "receiptDate": "2016.08.03",
        "receiptNumber": "1-1-2016-0756239-25"
      },
      {
        "commonCodeName": "보정승인 (Acceptance of amendment)",
        "documentEngName": "[Amendment to Description, etc.] Amendment",
        "documentName": "[명세서등 보정]보정서",
        "receiptDate": "2016.08.03",
        "receiptNumber": "1-1-2016-0756241-17"
      },
      {
        "commonCodeName": "발송처리완료 (Completion of Transmission)",
        "documentEngName": "Decision to grant",
        "documentName": "등록결정서",
        "receiptDate": "2016.11.01",
        "receiptNumber": "9-5-2016-0788888-77"
      },
      {
        "commonCodeName": "수리 (Accepted)",
        "documentEngName": "",
        "documentName": "특허고객번호 정보변경(경정)신고서·정정신고서",
        "receiptDate": "2023.09.06",
        "receiptNumber": "4-1-2023-5233653-65"
      }
    ]
  },
  "imagePathInfo": {
    "docName": "1020150025384.jpg",
    "largePath": "http://plus.kipris.or.kr/openapi/fileToss.jsp?arg=2ba38663aa11ff0f6ca91af6061a2e008c617639122437994f2329b74edad6fb71f06ecde8ae85f92a6dabb309869e6a2c81f4bdbf72bff4d7729522d505099848208d906924d135",
    "path": "http://plus.kipris.or.kr/openapi/fileToss.jsp?arg=ed43a0609e94d6e22d01c5c32ba711cf5639fe61d5925ad2f397018365faec6d9bf5f23b327ae9fd2d8cf4a641f1eefb2ea61fc6ec14008311ea79bb24fdcbdc003767942c1f9b8e"
  },
  "rndInfoArray": {
    "rndInfo": [
      {
        "rndDepartmentName": "교육과학기술부",
        "rndDuration": "2014.08.01 ~ 2015.01.31",
        "rndManagingInstituteName": "(재)한국연구재단",
        "rndProjectName": "산학협력선도대학(LINC)육성사업 / LINK(기업지원) / 기술개발과제(3차)",
        "rndSpecialInstituteName": "(재)한국연구재단",
        "rndTaskContribution": "1/2",
        "rndTaskName": "다중 표적 단백질 Kinase 신호전달 억제제의 라이브러리 합성",
        "rndTaskNumber": "201400000002065"
      },
      {
        "rndDepartmentName": "미래창조과학부",
        "rndDuration": "2014.11.01 ~ 2015.07.31",
        "rndManagingInstituteName": "(재)한국연구재단",
        "rndProjectName": "이공분야 기초연구사업 / 신진연구지원사업 / 여성과학자",
        "rndSpecialInstituteName": "(재)한국연구재단",
        "rndTaskContribution": "1/2",
        "rndTaskName": "선택적 Raf kinase 저해를 통한 표적 항암제 연구",
        "rndTaskNumber": "2014R1A1A3051648"
      }
    ]
  }
}